ETR:MDG1 - MediGene Stock Price, News, & Analysis

€7.50
+0.05 (+0.67 %)
(As of 06/26/2019 01:51 PM ET)
Today's Range
€7.41
Now: €7.50
€7.65
50-Day Range
€7.41
MA: €7.98
€8.99
52-Week Range
€7.20
Now: €7.50
€15.55
Volume43,585 shs
Average Volume306,207 shs
Market Capitalization$184.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-89-2000330

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.55 million
Cash Flow€2.27 per share
Book Value€4.16 per share

Profitability

Miscellaneous

Employees106
Market Cap$184.06 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

MediGene (ETR:MDG1) Frequently Asked Questions

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

What price target have analysts set for MDG1?

2 brokers have issued 1-year price targets for MediGene's shares. Their predictions range from €10.00 to €11.00. On average, they expect MediGene's share price to reach €10.50 in the next twelve months. This suggests a possible upside of 40.1% from the stock's current price. View Analyst Price Targets for MediGene.

What is the consensus analysts' recommendation for MediGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MediGene.

Has MediGene been receiving favorable news coverage?

News headlines about MDG1 stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MediGene earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for MediGene.

Who are some of MediGene's key competitors?

What other stocks do shareholders of MediGene own?

Who are MediGene's key executives?

MediGene's management team includes the folowing people:
  • Dr. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)
  • Dr. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management Board
  • Dr. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)
  • Mr. Axel-Sven Malkomes, CFO, Chief Bus. Devel. Officer and Member of Exec. Management Board
  • Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board

What is MediGene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €7.50.

How big of a company is MediGene?

MediGene has a market capitalization of $184.06 million and generates $7.55 million in revenue each year. MediGene employs 106 workers across the globe.View Additional Information About MediGene.

What is MediGene's official website?

The official website for MediGene is http://www.medigene.de/.

How can I contact MediGene?

MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.


MarketBeat Community Rating for MediGene (ETR MDG1)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe MDG1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Featured Article: Forex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel